🔬 Did you know? .An Antibody-Drug Conjugate (ADC) is an innovative therapy primarily used in oncology. 👨‍⚕️ Why does it matter?  .ADCs allow for the targeted delivery of powerful cytotoxic drug, significantly reducing toxicity compared to conventional chemotherapy. $IPH $IPHA

🔬 Meet Eric Vivier, Chief Scientific Officer of Innate Pharma, who will be speaker at FOCIS 2025 on June 25, during an educational session to highlight the potential of innate immunity in cancer treatment. $IPH $IPHA #InnatePharma #FOCiS2025 #Immunotherapy @FOCISimmunology.

We’re pleased to share that the long-term follow-up data from the TELLOMAK trial, recently presented at ASCO, will be featured again as an encore presentation at the upcoming ICML in Lugano. $IPH $IPHA #InnatePharma #Lymphoma #ICML @icmlconf.

#MeetInnate . Come and meet members of our management team at the next IR conferences below 🚀 . $IPH $IPHA #InnatePharma #IRmeeting #InvestorRelations.

🚀 Innate Pharma at #EHA2025 . Our CEO, Jonathan Dickinson, met with @bradloncar of @BioTechTV during the EHA 2025 congress to discuss our latest pipeline progress and our upcoming catalysts. 🧬 A great opportunity to share how Innate Pharma is advancing science to improve.

Innate Pharma highlights preclinical antitumor activity of IPH6501 in diffuse large B-cell lymphoma and follicular lymphoma and combination potential with R-CHOP 🔬. More info in the press release: $IPH $IPHA #InnatePharma #EHA2025 #Lymphoma

#clubdesactionnaires . Découvrez le récap des actualités de la société dans la dernière lettre aux actionnaires. 🚀   . Vous êtes actionnaires et vous souhaitez recevoir la lettre : . $IPH $IPHA #InnatePharma #Investisseur #LettreAuxActionnaires

Our next IR conference 🚀 . Don't hesitate to contact us if you'd like to meet and talk. $IPH $IPHA #InnatePharma #Congress #IRmeeting.

Innate Pharma highlights durable responses to lacutamab in Sézary syndrome and mycosis fungoides 📊. More info in our press release: $IPH $IPHA #InnatePharma #ASCO2025 @ASCO

En direct de notre Assemblée Générale 🗳️ . Merci à tous les actionnaires présents sur place pour votre implication et pour nos échanges. 🙏 . $IPH $IPHA #InnatePharma #AssembléeGénérale #AG

🗳️ J-2 avant notre Assemblée Générale Mixte se tiendra le 22 mai 2025 à 10h30 dans nos locaux à Marseille. Pour plus d’informations : . $IPH $IPHA #AssembléeGénérale #InnatePharma #Actionnaires #Biotech

Innate Pharma highlights abstracts selected for ASCO 2025 Annual Meeting 🚀📰. More info in our press release: $IPH $IPHA #InntatePharma #ASCO2025 #Abstracts @ASCO

We are pleased to announce that an abstract regarding IPH6501 has been selected selected for the #EHA2025 Congress. In addition, an abstract related to SAR’514/IPH6401 was accepted for online publication. 📢. 🔗 $IPH $IPHA #InnatePharma @EHA_Hematology

👨‍💻 Replay of the conference call for our first quarter financial results and business updates   . 📊 In case you missed it, the replay of the presentation and the Q&A session is now available: . $IPH $IPHA #InnatePharma #Q12025 #Webinar #BusinessResults

Innate Pharma reports first quarter 2025 business update and financial results 📊🔬. 📢 Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. ET. More info in the press release:  $IPH $IPHA #InnatePharma #Q12025 #Webinar #Results

La prochaine Assemblée Générale Mixte se tiendra le 22 mai 2025 à 10h30 dans nos locaux à Marseille. Pour plus d’informations : . $IPH $IPHA #AssembléeGénérale #InnatePharma #Actionnaires #Biotech

Innate Pharma announces conference call and webcast for Q1 2025 Business Update 👨‍💻. 👉 In addition, members of the executive management team will be meeting with investors in New York and Boston from May 13 to May 14, 2025. $IPH $IPHA #InnatePharma #Webinar #Q12025.

Innate pharma highlights preclinical anti-tumor efficacy data of its antibody drug conjugate IPH4502 at the AACR 2025 annual meeting 👇.🧬IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors.

Innate Pharma announces €15 M investment by Sanofi 📢. 👉 Investment is in addition to the ongoing partnership as shared previously, including continuing the development of BCMA targeting ANKET® program in autoimmune indications, and more. For more info, read the press release:

Innate Pharma regains its rights on CD123 targeting ANKET® and announces Sanofi’s intention to make a strategic investment in the Company. ➡️ Innate to regain its rights on CD123 targeting ANKET® SAR443579 (SAR’579) /IPH6101 currently in development for AML.➡️ Potential